Nanocomposite orthopaedic bone cement combining long-acting dual antimicrobial drugs

Yang, Lirong, Yergeshov, Abdulla A., Al-Thaher, Yazan, Avdokushina, Svetlana, Statsenko, Evgeny, Abdullin, Timur I. and Prokopovich, Polina ORCID: https://orcid.org/0000-0002-5700-9570 2023. Nanocomposite orthopaedic bone cement combining long-acting dual antimicrobial drugs. Biomaterials Advances 153 , 213538. 10.1016/j.bioadv.2023.213538

Preview

PDF - Published Version Available under License Creative Commons Attribution. Download (13MB) | Preview

Abstract

Antibiotic loaded bone cements are widely used in total joint replacement (TJR); despite many limitations such as a burst release which leads to antibiotic concentration below inhibitory levels and possibly contributing to the selection of antibiotic resistant strains. In order to address such limitations and to simultaneously address antibiotic resistance and short-term antimicrobial activity, we developed a nanocomposite bone cement capable of providing a controlled release of antimicrobial agents from bone cement to act as prophylaxis or treatment against prosthetic joint infections (PJIs). Gentamicin and chlorhexidine were loaded in combination on silica nanoparticles surface using layer-by-layer coating technique (LbL) combining hydrolysable and non-hydrolysable polymers. The drug release from the nanocomposite continued for >50 days at concentrations higher than the commercial formulation containing the same amount of antimicrobial drugs, where burst release for few days were observed. Moreover, the nanocomposite bone cement showed superior antimicrobial inhibition without adversely affecting the mechanical properties or the ability of osteoblasts to grow. In vivo experiments with an infected bone lesion model along with mass-spectrometric analysis also provided further evidence of efficacy and safety of the implanted nanocomposite material as well as its prolonged drug eluting profile. The developed nanocomposite bone cement has the potential to reduce PJIs and enable treatment of resistant established infections; moreover, the newly developed LbL based nano-delivery system may also have wider applications in reducing the threat posed by antimicrobial resistance.

Item Type:	Article
Date Type:	Published Online
Status:	Published
Schools:	Pharmacy
Publisher:	Elsevier
ISSN:	2772-9508
Funders:	Wellcome Trust
Date of First Compliant Deposit:	20 July 2023
Date of Acceptance:	22 June 2023
Last Modified:	16 Sep 2023 00:32
URI:	https://orca.cardiff.ac.uk/id/eprint/161150

Actions (repository staff only)

Edit Item